Do we have at last the evidence for clinical efficacy of pharmacologic intervention aimed at HDL lipoproteins? Commentary on ARBITER 6 HALTS trial Commentary
Article Sidebar
Published:
Dec 31, 2010
Keywords:
HDL-cholesterol, niacin, ezetimibe, intima-media thickness (IMT)
Main Article Content
Abstract
The paper discusses role of HDL lipoproteins in coronary heart disease development. Potential role of pharmacologic modification aimed at low HDL cholesterol level is underlined in the light of ARBITER 6 HALTS trial results achieved with niacin.
Article Details
How to Cite
Pikto-Pietkiewicz , W. (2010). Do we have at last the evidence for clinical efficacy of pharmacologic intervention aimed at HDL lipoproteins? Commentary on ARBITER 6 HALTS trial. Medycyna Faktow (J EBM), 3(4(9), 54-60. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2564
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wei L., Ebrahim S., Bartlett C. et al.: Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821.
2. Brugts J.J., Yetgin T., Hoeks S.E. et al.: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
3. Gordon T., Castelli W.P., Hjortland M.C. et al.: High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am. J. Med. 1977; 62: 707-14.
4. Assmann G., Schulte H., von Eckardstein A., Huang Y.: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(suppl): S11-20.
5. Sacks F.; for the Expert Group on HDL Cholesterol: The Role of High-Density Lipoprotein ( HDL) Cholesterol in the Prevention and Treatment of Coronary Heart Disease: Expert Group Recommendations. Am. J. Cardiol. 2002; 90: 139-143.
6. Barter P., Gotto A.M., LaRosa J.C. et al.: HDL-cholesterol, very low levels of LDL cholesterol and cardiovascular events. N. Engl. J. Med. 2007; 357: 1301-10.
7. Fruchart J.C., Sacks F., Hermans M.P. et al.; The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. Am. J. Cardiol. 2008; 102(suppl): 1K-34K.
8. Mukamal K.J., Chen C.M., Rao S.R. et al.: Alcohol Consumption and Cardiovascular Mortality Among U.S. Adults, 1987- 2002. Journal of the American College of Cardiology 2010; 55(13): 1328-1335.
9. Rubins H.B., Robins S.J., Collins D. et al.: Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. N. Engl. J. Med. 1999; 341: 410-418.
10. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus [online: 10.1056/nejmoa1001282 nejm.org].
11. Barter P.J., Caulfield M., Eriksson M. et al.: Effects of Torcetrapib in Patients at High Risk for Coronary Events. N. Engl. J. Med. 2007; 357: 2109-22.
12. Singh I.M., Shishehbor M.H., Ansell B.J.: High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298: 786-98 [errata: JAMA 2007; 298: 1516].
13. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 15; 2(8403): 600-4.
14. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
15. Coronary Drug Project Research Group. Clofibrate and niacin coronary heart disease. JAMA 1975; 231: 360-381.
16. Lamon-Fava S., Diffenderfer M.R., Barret P.H. et al.: Extended released niacin alters metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscl. Thromb. Vasc. Biol. 2008; 28: 1672-8.
17. Taylor A.J., Sullenberger L.E., Lee H.J. et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
18. Brown B.G., Zhao X.Q., Chait A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592.
19. Taylor A.J., Villines T.C., Stanek E.J. et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 2009; 361: 2113-22.
20. Crouse J.R. III, Raichlen J.S., Riley W.A. et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344-53.
21. Villines T.C., Stanek E.J., Devine P.J. et al.: The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 – HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J. Am. Coll. Cardiol. 2010; 55: 2721-2726.
22. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
23. Raal F.J., Santos R.D., Blom D.J. et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010 [DOI: 10.1016/S0140-6736(10)60284-X].
24. Nissen S.E., Nicholls S.J., Wolski K. et al.: Effects of a potent and selective PPAR-{:alpha:} agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. JAMA 2007; 297: 1362-1373.
2. Brugts J.J., Yetgin T., Hoeks S.E. et al.: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
3. Gordon T., Castelli W.P., Hjortland M.C. et al.: High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am. J. Med. 1977; 62: 707-14.
4. Assmann G., Schulte H., von Eckardstein A., Huang Y.: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(suppl): S11-20.
5. Sacks F.; for the Expert Group on HDL Cholesterol: The Role of High-Density Lipoprotein ( HDL) Cholesterol in the Prevention and Treatment of Coronary Heart Disease: Expert Group Recommendations. Am. J. Cardiol. 2002; 90: 139-143.
6. Barter P., Gotto A.M., LaRosa J.C. et al.: HDL-cholesterol, very low levels of LDL cholesterol and cardiovascular events. N. Engl. J. Med. 2007; 357: 1301-10.
7. Fruchart J.C., Sacks F., Hermans M.P. et al.; The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. Am. J. Cardiol. 2008; 102(suppl): 1K-34K.
8. Mukamal K.J., Chen C.M., Rao S.R. et al.: Alcohol Consumption and Cardiovascular Mortality Among U.S. Adults, 1987- 2002. Journal of the American College of Cardiology 2010; 55(13): 1328-1335.
9. Rubins H.B., Robins S.J., Collins D. et al.: Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. N. Engl. J. Med. 1999; 341: 410-418.
10. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus [online: 10.1056/nejmoa1001282 nejm.org].
11. Barter P.J., Caulfield M., Eriksson M. et al.: Effects of Torcetrapib in Patients at High Risk for Coronary Events. N. Engl. J. Med. 2007; 357: 2109-22.
12. Singh I.M., Shishehbor M.H., Ansell B.J.: High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007; 298: 786-98 [errata: JAMA 2007; 298: 1516].
13. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 15; 2(8403): 600-4.
14. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
15. Coronary Drug Project Research Group. Clofibrate and niacin coronary heart disease. JAMA 1975; 231: 360-381.
16. Lamon-Fava S., Diffenderfer M.R., Barret P.H. et al.: Extended released niacin alters metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscl. Thromb. Vasc. Biol. 2008; 28: 1672-8.
17. Taylor A.J., Sullenberger L.E., Lee H.J. et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
18. Brown B.G., Zhao X.Q., Chait A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-1592.
19. Taylor A.J., Villines T.C., Stanek E.J. et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 2009; 361: 2113-22.
20. Crouse J.R. III, Raichlen J.S., Riley W.A. et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344-53.
21. Villines T.C., Stanek E.J., Devine P.J. et al.: The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 – HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration. J. Am. Coll. Cardiol. 2010; 55: 2721-2726.
22. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
23. Raal F.J., Santos R.D., Blom D.J. et al.: Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010 [DOI: 10.1016/S0140-6736(10)60284-X].
24. Nissen S.E., Nicholls S.J., Wolski K. et al.: Effects of a potent and selective PPAR-{:alpha:} agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. JAMA 2007; 297: 1362-1373.